Benzinga | Sep 28, 2021 04:59AM EDT

Citigroup Upgrades Harpoon Therapeutics to Buy, Announces $16 Price Target

Citigroup analyst Yigal Nochomovitz upgrades Harpoon Therapeutics (NASDAQ:HARP) from Neutral to Buy and announces $16 price target.